Prostate Cancer Awareness Week
(pcaw.org) has compiled newsbytes on the prostate. Prostate Cancer
Awareness Month is September, and Prostate Cancer Awareness Week, the
period set aside for free or low-cost screenings, runs September
21-27, 2015. Information about the Prostate is added weekly. Also see
Archives 2 and 3.
Prostate Cancer Deaths Expected to Decrease by
Nearly 7 Percent in 2015
Newly released figures reveal that the death rate for prostate cancer
is expected to decrease by nearly 7 percent in 2015, with an
estimated 27,540 lives lost to the disease. In addition, new cases of
prostate cancer are also expected to decrease by more than 5 percent,
to 220,800 new cases. While this is good news, these numbers
represent real men and families who are suffering every day. Knowing
your PSA score as well as being aware of the full spectrum of
treatments and tactics gives a man the best chance against prostate
More Sexual Partners may Increase Risk
of Prostate Cancer
Men should already know that sex with multiple partners, especially
unprotected sex, can increase their risk of contracting HIV and
various venereal diseases. They also can add that it may raise their
odds of getting prostate cancer in middle age, according to a study
published in a recent issue of the American Journal of
Vasectomy Does Not Increase Prostate
Contrary to some earlier studies, a new study funded in part by the
National Institute of Child Health and Human Development (NICHD)
found that men who undergo vasectomies are no more likely to develop
prostate cancer than are men who do not.
Hot flashes aren't just for menopausal
women these days
Hot flashes no longer discriminate because of age or gender. New-wave
drugs that tweak hormones - estrogen and its male cousin,
testosterone - have turned up the heat on an age-old phenomenon. Men
and women getting medical treatment for a variety of reasons - breast
and prostate cancer prevention and fertility enhancement, for example
- now break out in a sweat when they least expect it.
Prostate Cancer Clinical Research
Call 1-888-742-7876 to find out more information about a clinical
research study to reduce the incidence of prostate cancer in men who
are at increased risk.
Calculate Your Odds Against Prostate
Researchers have created an online calculator that provides prostate
cancer patients with personalized 10-year survival predictions.
Developed by the Josephine Ford Cancer Center and the Artificial
Neural Networks in Prostate Cancer Project, the calculator makes its
prognosis based on a patient's age, race, clinical measures and the
kind of prostate cancer treatment he's receiving. Survival
probability estimates are based on data from over 1600 men with
clinically localized prostate cancer.
Valera Seeks FDA Approval for Prostate
Valera Pharmaceuticals has submitted a New Drug Application (NDA) to
the Food and Drug Administration (FDA) for Vantas(TM), Valera's
long-acting implant for treating prostate cancer. Vantas(TM) has been
designed for the continuous 12-month administration of Histrelin, a
luteinizing hormone releasing hormone (LHRH) for the palliative
treatment of metastatic prostate cancer.
New Results in Breast and Prostate Cancer
Models Show Potential of ARIUS Antibodies-Tumor Suppression and
Increased Survival Following Treatment ARIUS Research Inc.
ARIUS Research Inc. announced today that the proceedings of the 94th
annual meeting of the American Association for Cancer Research (AACR)
will publish successful pre-clinical study results for three of their
novel anti-cancer antibodies. AR7BD-33-11A and AR1A245.6 have met a
number of significant endpoints including preventing development of
breast and prostate cancers in tumor prevention models and halting
tumor growth in a different, established tumor model. These
antibodies also significantly improved survival in animal models of
human cancer. A third antibody, AR7BDI-58, suppressed development of
another kind of breast cancer.
Source: Canada NewsWire
Inhibitors of Novel Cancer Target
Attack Tumor on Two Fronts-AACR Proceedings Highlight Research of
LPAAT-beta Inhibition By Cell Therapeutics, Inc. in Human Cell
In a plenary minisymposium on intracellular signaling published in
the Proceedings of the Annual Meeting of the American Association for
Cancer Research, Cell Therapeutics, Inc. presented data on a novel
cancer target, LPAAT-beta. The data suggest that the inhibition of
LPAAT-beta may impede the growth of tumors on two fronts, by
restricting the growth of supporting tissues such as blood vessels
and by removing a cofactor essential to tumor cell growth and
proliferation. Existing therapies typically use a single mechanism to
fight cancer, whereas, LPAAT-beta inhibitors appear to have a dual
function. In the published proceedings, CTI highlighted research on
signaling pathways which showed that inhibition of LPAAT-beta by
genetic knockdown with RNAi or with specific inhibitors of the enzyme
leads to tumor cell death through apoptosis. CTI's research also
suggests the enzyme plays an important role in cell types that are
critical in the formation of the support tissues (stroma) and the
abnormal blood vessels which support tumor growth and provide tumor
blood supply. "The discovery of a gene product that has critical
functions in the regulation of the Raf and other cancer-related
pathways as well as in the tissues supporting the tumor is intriguing
and suggests LPAAT-beta inhibition may be particularly effective in
treating cancer where therapies that use only a single mechanism for
fighting cancer have failed," said Jack W. Singer, M.D. and Research
Program Chair of CTI.
Source: PR Newswire
HRT Patches for Men: They help
in prostate cancer fight
Hormone patches normally worn by women to relieve menopausal symptoms
are helping men fight prostate cancer. They cut the supply of the
male hormone testosterone, which can encourage the growth of cancer
cells, according to experts.
Source: Daily Mail.
External Beam Radiotherapy can Relieve
Metastatic Bone Pain
"We have performed a clinical study to evaluate the relationship of
response to EBRT in terms of pain relief and improvement in quality
of life (QoL). We were also interested in the incidence of acute
toxicity with EBRT. We have prospectively evaluated 75 patients
(median age 68 years, range 64-79 years) with bone metastases from
prostate cancer treated with EBRT, radiographically documented from
June 1999 to September 2000," wrote G. Di Lorenzo and colleagues,
University of Naples.
Source: Cancer Weekly, www.ustoo.org/screamoutput/index.html
* * *
The 1990 Unofficial Census reported more than 20.5 million Americans
wear diapers.11 million of them adults.
Approvimately 90% of adults can be treated or cured of
incontinence but haven't sought professional help.
Disclaimer: pcaw.org is
produced by the National National Men's Resource Center. This web
site seeks to inform and educate men on the many issues that confront
them today regarding the possible dangers of prostate cancer.
Information presented in this free web site does not necessarily
represent the official position of NMRC. Moreover, information in
pcaw.org is culled from diverse web sites and information sources.
NMRC cannot guarantee the accuracy of these sources. Due to the
timeliness of the information, some links will change and/or
deactivate without notice.
Information is designed for educational purposes.
We are not engaged in rendering medical or psychological advice or
professional services. Any decisions should be made in conjunction
with your physician or therapist. We will not be liable for any
complications, injuries or other medical accidents arising from or in
connection with, the use of or reliance upon, any information on our
A service of The National Men's Resource Center
©1996-2019, The National Men's Resource Center